@article{oai:u-ryukyu.repo.nii.ac.jp:02016025,
 author = {比嘉, 保 and 芳原, 準男 and 比嘉, 小百合 and 砂川, 敦子 and Higa, Tamotsu and Hobara, Norio and Higa, Sayuri and Sunagawa, Atsuko},
 issue = {2},
 journal = {琉球医学会誌 = Ryukyu Medical Journal},
 month = {},
 note = {We analysed acceptance situation of Clinical Trial and Post Marketing Surveillance (PMS) from 1990 to 1995 in our hospital. Average acceptance number of Clinical Trial was 148 cases per year. Fifty-eight percent (58%) of new Clinical Trial was occupied by both the 1st and 3rd Department of Internal Medicine. Fifty-four percent (54%) of the trials was on antihypertensive agents and antimicrobial agents. Twelve cases were accepted in PMS from November 1995 to March 1996. Seven cases were accepted for Special lnvestigationn upon manufacturers request. Two Orphan Drugs were accepted for re-examination. In conclusion, less re-examination and more Special Investigation II is requested from the academic and economic standpoints., 論文},
 pages = {115--118},
 title = {[話題]琉球大学医学部附属病院における治験と市販後調査の受入状況},
 volume = {17},
 year = {1997}
}